Cochrane · systematic review · CD005647
Treatment for HIV‐associated cryptococcal meningitis
Tenforde, MW, Shapiro, AE, Rouse, B, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
21
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 5 · 23.8%Low 5 · 23.8%Moderate 10 · 47.6%High 1 · 4.8%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
One week of AmBd + 5FC compared to two weeks of AmBd + 5FC for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks One week of AmBd + 5FC vs two weeks of AmBd + 5FC | RR 0.62 [0.42, 0.93] | 1 study · 228 participants | Moderate Downgraded: imprecision |
One week of AmBd + 5FC compared to two weeks of AmBd + FLU for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks One week of AmBd + 5FC vs two weeks of AmBd + FLU | RR 0.58 [0.39, 0.86] | 1 study · 227 participants | Moderate Downgraded: imprecision |
One week of AmBd + 5FC compared to one week of AmBd + FLU for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks One week of AmBd + 5FC vs one week of AmBd + FLU | RR 0.49 [0.34, 0.72] | 1 study · 224 participants | Moderate Downgraded: imprecision |
One week of AmBd + 5FC compared to two weeks of 5FC + FLU for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks One week of AmBd + 5FC vs two weeks of 5FC + FLU | RR 0.68 [0.47, 0.99] | 1 study · 338 participants | Moderate Downgraded: imprecision |
Two weeks of 5FC + FLU compared to two weeks of AmBd + 5FC for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks Two weeks of 5FC + FLU vs two weeks of AmBd + 5FC | RR 0.92 [0.69, 1.23] | 1 study · 340 participants | Moderate Downgraded: imprecision |
Two weeks of 5FC + FLU compared to two weeks of AmBd + FLU for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks Two weeks of 5FC + FLU vs two weeks of AmBd + FLU | RR 0.85 [0.64, 1.13] | 1 study · 339 participants | Moderate Downgraded: imprecision |
Two weeks of AmBd + 5FC compared to two weeks of AmBd for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks Two weeks of AmBd + 5FC vs two weeks of AmBd | RR 0.66 [0.46, 0.95] | 2 studies · 231 participants | Moderate Downgraded: imprecision |
Two weeks of AmBd + FLU compared to two weeks of AmBd for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks Two weeks of AmBd + FLU vs two weeks of AmBd | RR 0.94 [0.55, 1.62] | 3 studies · 371 participants | Low Downgraded: imprecision, indirectness |
Two weeks of AmBd + 5FC compared to two weeks of AmBd + FLU for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks Two weeks of AmBd + 5FC vs two weeks of AmBd + FLU | RR 0.9 [0.69, 1.19] | 4 studies · 538 participants | Low Downgraded: imprecision, indirectness |
Two weeks of AmBd + FLU + steroids compared to two weeks of AmBd + FLU for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks Two weeks of AmBd + FLU + steroids vs two weeks of AmBd + FLU | RR 1.15 [0.93, 1.42] | 1 study · 450 participants | High |
One week of AmBd + FLU compared to two weeks of AmBd + FLU for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks One week of AmBd + FLU vs two weeks of AmBd + FLU | RR 1.18 [0.88, 1.58] | 1 study · 225 participants | Moderate Downgraded: imprecision |
One week of AmBd + FLU compared to two weeks of AmBd + 5FC for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks One week of AmBd + FLU vs two weeks of AmBd + 5FC | RR 1.27 [0.94, 1.72] | 1 study · 226 participants | Moderate Downgraded: imprecision |
One week of AmBd + FLU compared to two weeks of 5FC + FLU for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks One week of AmBd + FLU vs two weeks of 5FC + FLU | RR 1.39 [1.07, 1.8] | 1 study · 336 participants | Moderate Downgraded: imprecision |
Two weeks of FLU compared to two weeks of 5FC + FLU for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks Two weeks of FLU vs two weeks of 5FC + FLU | RR 1.46 [0.96, 2.23] | 2 studies · 98 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Two weeks of L‐AmB compared to two weeks of AmBd for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks Two weeks of L‐AmB vs two weeks of AmBd | RR 0.43 [0.04, 4.25] | 1 study · 28 participants | Very low Downgraded: risk of bias, imprecision |
Short‐course L‐AmB + FLU compared to two weeks of L‐AmB + FLU for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks Short‐course L‐AmB + FLU vs two weeks of L‐AmB + FLU | RR 1.03 [0.47, 2.25] | 1 study · 79 participants | Low Downgraded: imprecision |
Two weeks of AmBd + 5FC + FLU compared to two weeks of AmBd + 5FC for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks Two weeks of AmBd + 5FC + FLU vs two weeks of AmBd + 5FC | RR 2.81 [0.33, 24.16] | 1 study · 31 participants | Very low Downgraded: imprecision, indirectness |
Two weeks of AmBd + 5FC + FLU compared to two weeks of AmBd + FLU for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks Two weeks of AmBd + 5FC + FLU vs two weeks of AmBd + FLU | RR 0.43 [0.13, 1.37] | 1 study · 32 participants | Very low Downgraded: imprecision, indirectness |
Two weeks of AmBd + 5FC + FLU compared to two weeks of AmBd for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks Two weeks of AmBd + 5FC + FLU vs two weeks of AmBd | RR 1 [0.24, 4.23] | 1 study · 32 participants | Very low Downgraded: imprecision, indirectness |
One week of AmBd + 5FC + FLU compared to one week of AmBd + FLU for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks One week of AmBd + 5FC + FLU vs one week of AmBd + FLU | RR 0.86 [0.35, 2.1] | 1 study · 40 participants | Low Downgraded: imprecision |
Two weeks of AmBd + 5FC + IFNg compared to two weeks of AmBd + 5FC for HIV‐associated cryptococcal meningitis
Population: HIV‐infected individual with first episode of cryptococcal meningitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality: 10 weeks Two weeks of AmBd + 5FC + IFNg vs two weeks of AmBd + 5FC | RR 0.92 [0.48, 1.77] | 1 study · 88 participants | Low Downgraded: imprecision |